Nevertheless, HER2 amplification status showed no significant correlation with tumor mutational burden (TMB) (Table 2 and Supplementary Figure S2A), age (Supplementary Figure S2C), or tumor purity (Supplementary Figure S2D). Here, ERBB2 is linked to neoplasm.